Free Trial

Knight Therapeutics (KHTRF) Stock Price, News & Analysis

-0.07 (-1.59%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
100 shs
Average Volume
6,778 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
KHTRF stock logo

About Knight Therapeutics Stock (OTCMKTS:KHTRF)

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

KHTRF Stock Price History

KHTRF Stock News Headlines

Knight Therapeutics Inc.
RBC Capital Keeps Their Buy Rating on Knight Therapeutics (KHTRF)
Knight Therapeutics reports Q3 results
See More Headlines
Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Drug Manufacturers - Specialty & Generic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Not Optionable
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Jonathan Ross Goodman B.A. (Age 55)
    L.L.B., M.B.A., Executive Chairman
    Comp: $183.38k
  • Ms. Samira Sakhia BCom (Age 56)
    CA, CPA, MBA, President, CEO & Director
    Comp: $492.75k
  • Mr. Arvind Utchanah
    Chief Financial Officer
  • Ms. Amal Khouri B.Sc.
    M.B.A., Chief Business Officer
  • Mr. Jeff Martens
    Global Vice President of Commercial
  • Mr. Stephani Saverio
    Vice President of Business Development
  • Mr. Leopoldo Bosano
    Vice-President of Manufacturing & Operations
  • Ms. Monica Percario
    Global Vice President of Scientific Affairs
  • Mr. Henrique Dias
    Global Director of Marketing
  • Ms. Susan Caroline Emblem
    Global Vice President of Human Resources

KHTRF Stock Analysis - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KHTRF shares.
View KHTRF analyst ratings
or view top-rated stocks.

What is Knight Therapeutics' stock price target for 2024?

1 brokerages have issued 1-year price targets for Knight Therapeutics' stock. Their KHTRF share price targets range from $7.50 to $7.50. On average, they expect the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price.
View analysts price targets for KHTRF
or view top-rated stocks among Wall Street analysts.

How have KHTRF shares performed in 2024?

Knight Therapeutics' stock was trading at $3.96 at the beginning of the year. Since then, KHTRF shares have increased by 9.6% and is now trading at $4.34.
View the best growth stocks for 2024 here

How do I buy shares of Knight Therapeutics?

Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:KHTRF) was last updated on 5/23/2024 by Staff

From Our Partners